Empirical models for dosage optimization of four β-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin

Clinical Biochemistry

Volumn 43, Issue 6, 2010, Pages 589-598

  Delattre, Isabelle K ^a   Musuamba, Flora T ^a   Verbeeck, Roger K ^a   Dugernier, Thierry ^b   Spapen, Herbert ^c   Laterre, Pierre François ^d   Wittebole, Xavier ^d   Cumps, Jean ^a   Taccone, Fabio S ^e   Vincent, Jean Louis ^e   Jacobs, Frédérique ^e   Wallemacq, Pierre E ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b Clinique Saint Pierre of Ottignies   (Belgium)

^c UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^d CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^e ERASME HOSPITAL   (Belgium)

Author keywords

lactams; Amikacin; Multivariate analysis; Pharmacokinetics; Sepsis; Therapeutic drug monitoring

Indexed keywords

AMIKACIN; BETA LACTAM ANTIBIOTIC; BIOLOGICAL MARKER; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; VISNADINE;

ADULT; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; COLLOID; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG RETENTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK;

ADULT; AGED; AGED, 80 AND OVER; AMIKACIN; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CALIBRATION; CRITICAL ILLNESS; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EMPIRICAL RESEARCH; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, THEORETICAL; SEPSIS; YOUNG ADULT;

EID: 77950867085     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.12.007     Document Type: Article

References (59)

1. Vincent J.L., Sakr Y., Sprung C.L., et al. Sepsis occurrence in acutely ill patients investigators. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34:344-353.
2. Linde-Zwirble W.T., Angus D.C. Severe sepsis epidemiology: sampling, selection, and society. Crit Care 2004, 8:222-226.
3. Alberti C., Brun-Buisson C., Burchardi H., et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002, 28:108-121.
4. Dombrovskiy V.Y., Martin A.A., Sunderram J., Paz H.L. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007, 35:1244-1250.
5. Kollef M.H., Sherman G., Ward S., Fraser V.J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
6. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118:146-155.
7. Leibovici L., Shraga I., Drucker M., Konigsberger H., Samra Z., Pitlik S.D. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998, 244:379-386.
8. Harbarth S., Garbino J., Pugin J., Romand J.A., Lew D., Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003, 115:529-535.
9. MacArthur R.D., Miller M., Albertson T., et al. Adequacy of early empiric antibiotic treatment and survival in severe sepsis: experience from the MONARCS trial. Clin Infect Dis 2004, 38:284-288.
10. Deresinski S. Principles of antibiotic therapy in severe infections: optimizing the therapeutic approach by use of laboratory and clinical data. Clin Infect Dis 2007, 45:S177-S183.
11. Scaglione F. Can PK/PD be used in everyday clinical practice. Int J Antimicrob Agents 2002, 19:349-353.
12. Hyatt J.M., McKinnon P.S., Zimmer G.S., Schentag J.J. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 1995, 28:143-160.
13. Pea F., Viale P. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients. Clin Infect Dis 2006, 42:1764-1771.
14. Craig W.A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998, 26:1-10.
15. Schentag J.J., Swanson D.J., Smith I.L. Dual individualization: antibiotic dosage calculation from the integration of in-vitro pharmacodynamics and in-vivo pharmacokinetics. J Antimicrob Chemother 1985, 15:S47-57.
16. Schentag J.J., Ballow C.H., Paladino J.A., Nix D.E. Dual individualization with antibiotics: integrated antibiotic management strategies for use in hospitals. Applied pharmacokinetics. Principles of therapeutic drug monitoring 1992, Applied Therapeutics, Inc., Vancouver (WA), p.17.1-20. 3rd ed. W.E. Evans, J.J. Schentag, W.J. Jusko (Eds.).
17. Roberts J.A., Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006, 45:755-773.
18. Pea F., Viale P., Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin Pharmacokinet 2005, 44:1009-1034.
19. De Paepe P., Belpaire F.M., Buylaert W.A. Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock. Clin Pharmacokinet 2002, 41:1135-1151.
20. Power B.M., Forbes A.M., van Heerden P.V., Ilett K.F. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998, 34:25-56.
21. Mehrotra R., De Gaudio R., Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 2004, 30:2145-2156.
22. Bodenham A., Shelly M.P., Park G.R. The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin Pharmacokinet 1988, 14:347-373.
23. Mohr J.F., Wanger A., Rex J.H. Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients. Diagn Microbiol Infect Dis 2004, 48:125-130.
24. Bochud P.Y., Glauser M.P., Carlet J., Calandra T. Empirical antibiotic therapy for patients with severe sepsis and septic shock. The Sepsis Text 2002, 539-558. Kluwer Academic Publishers, Boston. J.L. Vincent, J. Carlet, S.M. Opal (Eds.).
25. Tod M.M., Padoin C., Petitjean O. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods. Clin Pharmacokinet 2001, 40:803-814.
26. Erdman S.M., Rodvold K.A., Pryka R.D. An updated comparison of drug dosing methods. Part III: aminoglycoside antibiotics. Clin Pharmacokinet 1991, 20:374-388.
27. Sawchuk R.J., Zaske D.E. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm 1976, 4:183-195.
28. Sawchuk R.J., Zaske D.E., Cipolle R.J., Wargin W.A., Strate R.G. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther 1977, 21:362-369.
29. The Sanford guide to antimicrobial therapy 2005-2006, Luxembourg edition, Belgian. 19th ed. J.P. Sanford, D.N. Gilbert, R.C. Moellering (Eds.).
30. Levy M.M., Fink M.P., Marshall J.C., et al. SCCM/ESICM/ACCP/ATS/SIS. 2001 SCCM/ESICM/ACCP/ATS/SIS. International Sepsis Definitions Conference. Crit Care Med 2003, 31:1250-1256.
31. Knaus W.A., Draper E.A., Wagner D.P., Zimmerman J.E. APACHE II: a severity of disease classification system. Crit Care Med 1985, 13:818-829.
32. Vincent J.L., Moreno R., Takala J., et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710.
33. Jolley M.E. Fluorescence polarization immunoassay for the determination of therapeutic drug levels in human plasma. J Anal Toxicol 1981, 5:236-240.
34. Abbott Laboratories Diagnostics Division. TDxFLx/TDx assays manual. 1990.
35. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Q2(R1); Validation of analytical procedures: text and methodology. Nov 2005. Available at: Accessed November 2, 2005. http://www.ich.org/LOB/media/MEDIA417.pdf.
36. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). Guidance for industry: bioanalytical method validation. May 2001. Available at: Accessed November 2, 2005. http://www.fda.gov/cder/Guidance/4252fnl.pdf.
37. Leal T., Parez J.J., Vanbinst R., Wallemacq P.E. Computerized approach to monitoring aminoglycosides. Clin Chem 1991, 37:1415-1419.
38. Sheiner L.B., Beal S.L. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981, 9:503-512.
39. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
40. Levey A.S., Greene T., Kusek J.W., Beck G.J. A simplified equation to predict glomerular filtration rate from serum creatinine [abstract]. J Am Soc Nephrol 2000, 11:A0828.
41. Glantz S.A., Slinker B.K. Selecting the best regression model. Primer of Applied Regression and Analysis of Variance 2000, 241-273. McGraw-Hill, Inc., New York (NY). 2nd ed. S.A. Glantz, B.K. Slinker (Eds.).
42. Brendel K., Dartois C., Comets E. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007, 46:221-234.
43. Panomvana D., Kiatjaroensin S.A., Phiboonbanakit D. Correlation of the pharmacokinetic parameters of amikacin and ceftazidime. Clin Pharmacokinet 2007, 46:859-866.
44. Craig W.A., Kunin C.M. Significance of serum protein and tissue binding of antimicrobial agents. Annu Rev Med 1976, 27:287-300.
45. Rolinson G.N. The significance of protein binding of antibiotics in antibacterial chemotherapy. J Antimicrob Chemother 1980, 6:311-317.
46. Shyu W.C., Quintiliani R., Nightingale C.H., Dudley M.N. Effect of protein binding on drug penetration into blister fluid. Antimicrob Agents Chemother 1988, 32:128-130.
47. Compendium 2003, Association Générale de l'Industrie du Médicament asbl. 21st ed.
48. Lovich M.A., Creel C., Hong K., Hwang C.W., Edelman E.R. Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. J Pharm Sci 2001, 90:1324-1335.
49. Taeschner W., Vozeh S. Pharmacokinetic drug data. Clinical Pharmacokinetics. Drug data handbook 1998, Adis International, Auckland (NZ). 3rd ed. N.H.G. Holford (Ed.).
50. Wise R., Logan M., Cooper M., Ashby J.P., Andrews J.M. Meropenem pharmacokinetics and penetration into an inflammatory exudate. Antimicrob Agents Chemother 1990, 34:1515-1517.
51. Zaske D.E., Cipolle R.J., Strate R.J. Gentamicin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function. Surgery 1980, 87:164-169.
52. Zaske D.E., Cipolle R.J., Rotschafer J.C., Solem L.D., Mosier N.R., Strate R.G. Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations. Antimicrob Agents Chemother 1982, 21:407-411.
53. Zaske D.E., Irvine P., Strand L.M., Strate R.G., Cipolle R.J., Rotschafer J. Wide interpatient variations in gentamicin dosage requirements for geriatric patients. JAMA 1982, 248:3122-3126.
54. Touw D.J., Neef C., Thomson A.H., Vinks A.A. Cost-Cost-Effectiveness of Therapeutic Drug Monitoring Committee of the International Association for Therapeutic Drug Monitoring and Clinical Toxicology. Cost-effectiveness of therapeutic drug monitoring: a systematic review. Ther Drug Monit 2005, 27:10-17.
55. Mayersohn M.B. Special pharmacokinetic considerations in the elderly. Applied pharmacokinetics. Principles of therapeutic drug monitoring 1992, Applied Therapeutics, Inc., Vancouver (WA), p.9.1-43. 3rd ed. W.E. Evans, J.J. Schentag, W.J. Jusko (Eds.).
56. Turnidge J.D. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998, 27:10-22.
57. Moore R.D., Lietman P.S., Smith C.R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987, 155:93-99.
58. Lacy M.K., Nicolau D.P., Nightingale C.H., Quintiliani R. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998, 27:23-27.
59. Schentag J.J., Nix D.E., Forrest A., Adelman M.H. AUIC-the universal parameter within the constraint of a reasonable dosing interval. Ann Pharmacother 1996, 30:1029-1031.